Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 19/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | HTR1F | P30939 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309448 | 0.90 | PPARG (0.48) | PTGES2HTR6HTR1ADRD2HTR1D | |
| SCHEMBL352081 | 0.81 | PPARG (0.61) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL351468 | 0.81 | PPARG (0.49) | PTGES2HTR6HTR1ADRD2HTR1D | |
| SCHEMBL352324 | 0.81 | PPARG (0.49) | PTGES2HTR6HTR1ADRD2HTR1D | |
| SCHEMBL352407 | 0.70 | PPARG (0.51) | PTGES2HTR6HTR1ADRD2HTR1D | |
| SCHEMBL13239982 | 0.69 | HTR6 (0.69) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL350435 | 0.68 | HTR6 (0.48) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL352179 | 0.68 | PPARG (0.66) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL352198 | 0.68 | PPARG (0.55) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL352767 | 0.68 | PPARG (0.67) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | PTGES2 187/4885HTR6 1985/4885HTR1A 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.